Molgramostim inhalation - Savara Pharmaceuticals

Drug Profile

Molgramostim inhalation - Savara Pharmaceuticals

Alternative Names: GM-CSF inhalation - Savara; Inhalation rhGM-CSF; Molgradex; Nebulised recombinant human GM-CSF - Savara

Latest Information Update: 10 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Serendex Pharmaceuticals
  • Developer Savara Pharmaceuticals
  • Class Chemoprotectants; Granulocyte-macrophage colony-stimulating factors; Recombinant proteins
  • Mechanism of Action Granulocyte macrophage colony stimulating factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary alveolar proteinosis
  • New Molecular Entity No

Highest Development Phases

  • Phase III Pulmonary alveolar proteinosis
  • Phase II Respiratory distress syndrome
  • Phase I Bronchiectasis; Cystic fibrosis

Most Recent Events

  • 08 Nov 2017 Savara Pharmaceuticals plans a phase IIa trial for non-tuberculosis Mycobacterial infections
  • 07 Jun 2017 Phase-III clinical trials in Pulmonary alveolar proteinosis in Germany, Netherlands, France, Israel, Japan, Greece, Spain, Italy, Russia, Switzerland, United Kingdom and Denmark (Inhalation)
  • 07 Jan 2017 Savara plans a pivotal clinical trial for Pulmonary alveolar proteinosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top